Annual Net Income
-$70.80 M
+$31.46 M+30.77%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual net profit is currently -$70.80 million, with the most recent change of +$31.46 million (+30.77%) on 31 December 2023. During the last 3 years, it has fallen by -$25.40 million (-55.96%). EYPT annual net income is now -908.81% below its all-time high of $8.75 million, reached on 30 June 2010.EYPT Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$29.36 M
+$1.47 M+4.75%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly net profit is currently -$29.36 million, with the most recent change of +$1.47 million (+4.75%) on 30 September 2024. Over the past year, it has dropped by -$16.75 million (-132.80%). EYPT quarterly net income is now -178.17% below its all-time high of $37.56 million, reached on 30 September 2006.EYPT Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$103.57 M
-$16.75 M-19.29%
30 September 2024
Summary:
EyePoint Pharmaceuticals TTM net profit is currently -$103.57 million, with the most recent change of -$16.75 million (-19.29%) on 30 September 2024. Over the past year, it has dropped by -$3.42 million (-3.42%). EYPT TTM net income is now -568.00% below its all-time high of $22.13 million, reached on 30 September 2006.EYPT TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +30.8% | -132.8% | -3.4% |
| 3 y3 years | -56.0% | -75.9% | -90.2% |
| 5 y5 years | -58.3% | -87.7% | -123.3% |
EYPT Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -56.0% | +30.8% | -132.8% | +32.4% | -90.2% | +2.3% |
| 5 y | 5 years | -58.3% | +30.8% | -672.5% | +32.4% | -156.8% | +2.3% |
| alltime | all time | -908.8% | +31.7% | -178.2% | +53.8% | -568.0% | +2.3% |
EyePoint Pharmaceuticals Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$29.36 M(-4.8%) | -$103.57 M(+19.3%) |
| June 2024 | - | -$30.83 M(+5.3%) | -$86.82 M(+10.0%) |
| Mar 2024 | - | -$29.28 M(+107.7%) | -$78.92 M(+11.5%) |
| Dec 2023 | -$70.80 M(-30.8%) | -$14.10 M(+11.8%) | -$70.80 M(-29.3%) |
| Sept 2023 | - | -$12.61 M(-45.0%) | -$100.15 M(-5.5%) |
| June 2023 | - | -$22.92 M(+8.3%) | -$105.96 M(+3.4%) |
| Mar 2023 | - | -$21.16 M(-51.3%) | -$102.44 M(+0.2%) |
| Dec 2022 | -$102.25 M(+75.0%) | -$43.45 M(+135.9%) | -$102.25 M(+30.7%) |
| Sept 2022 | - | -$18.42 M(-5.1%) | -$78.23 M(+2.3%) |
| June 2022 | - | -$19.41 M(-7.5%) | -$76.51 M(+14.0%) |
| Mar 2022 | - | -$20.98 M(+7.9%) | -$67.11 M(+14.9%) |
| Dec 2021 | -$58.42 M(+28.7%) | -$19.43 M(+16.4%) | -$58.42 M(+7.3%) |
| Sept 2021 | - | -$16.70 M(+66.8%) | -$54.45 M(+31.0%) |
| June 2021 | - | -$10.01 M(-18.5%) | -$41.56 M(-6.6%) |
| Mar 2021 | - | -$12.28 M(-20.6%) | -$44.50 M(-2.0%) |
| Dec 2020 | -$45.39 M(-20.1%) | -$15.47 M(+307.0%) | -$45.39 M(+12.5%) |
| Sept 2020 | - | -$3.80 M(-70.6%) | -$40.34 M(-22.7%) |
| June 2020 | - | -$12.95 M(-1.7%) | -$52.18 M(+2.9%) |
| Mar 2020 | - | -$13.17 M(+26.6%) | -$50.73 M(-10.7%) |
| Dec 2019 | -$56.79 M(+27.0%) | -$10.41 M(-33.5%) | -$56.79 M(+22.4%) |
| Sept 2019 | - | -$15.65 M(+36.1%) | -$46.38 M(-27.4%) |
| June 2019 | - | -$11.50 M(-40.2%) | -$63.86 M(-26.4%) |
| Mar 2019 | - | -$19.24 M(-41.9%) | -$86.79 M(+8.1%) |
| Dec 2018 | -$44.72 M(-15.9%) | - | - |
| Sept 2018 | - | -$33.13 M(-3.8%) | -$80.31 M(+51.0%) |
| June 2018 | -$53.17 M(+187.6%) | -$34.43 M(+393.4%) | -$53.17 M(+113.9%) |
| Mar 2018 | - | -$6.98 M(+20.7%) | -$24.86 M(+8.0%) |
| Dec 2017 | - | -$5.78 M(-3.4%) | -$23.02 M(+33.0%) |
| Sept 2017 | - | -$5.98 M(-2.2%) | -$17.31 M(-6.4%) |
| June 2017 | -$18.48 M(-14.2%) | -$6.12 M(+19.0%) | -$18.48 M(-1.4%) |
| Mar 2017 | - | -$5.14 M(+7571.6%) | -$18.76 M(+0.5%) |
| Dec 2016 | - | -$67.00 K(-99.1%) | -$18.66 M(-21.5%) |
| Sept 2016 | - | -$7.16 M(+12.1%) | -$23.78 M(+10.3%) |
| June 2016 | -$21.55 M(-439.5%) | -$6.39 M(+26.7%) | -$21.55 M(+6.1%) |
| Mar 2016 | - | -$5.04 M(-2.8%) | -$20.31 M(+0.2%) |
| Dec 2015 | - | -$5.19 M(+5.1%) | -$20.26 M(+5.8%) |
| Sept 2015 | - | -$4.93 M(-4.1%) | -$19.15 M(-401.7%) |
| June 2015 | $6.35 M(-147.5%) | -$5.15 M(+3.0%) | $6.35 M(-15.7%) |
| Mar 2015 | - | -$5.00 M(+22.7%) | $7.53 M(-27.2%) |
| Dec 2014 | - | -$4.08 M(-119.8%) | $10.34 M(-5.1%) |
| Sept 2014 | - | $20.57 M(-618.4%) | $10.90 M(-181.6%) |
| June 2014 | -$13.36 M(+12.2%) | -$3.97 M(+81.4%) | -$13.36 M(+0.1%) |
| Mar 2014 | - | -$2.19 M(-37.8%) | -$13.34 M(-4.4%) |
| Dec 2013 | - | -$3.51 M(-4.7%) | -$13.94 M(+6.9%) |
| Sept 2013 | - | -$3.69 M(-6.6%) | -$13.04 M(+9.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | -$11.90 M(-52.1%) | -$3.95 M(+41.3%) | -$11.90 M(+16.5%) |
| Mar 2013 | - | -$2.79 M(+7.1%) | -$10.21 M(+1.1%) |
| Dec 2012 | - | -$2.61 M(+2.2%) | -$10.11 M(-59.5%) |
| Sept 2012 | - | -$2.55 M(+12.8%) | -$24.96 M(+0.5%) |
| June 2012 | -$24.84 M(+187.8%) | -$2.26 M(-15.8%) | -$24.84 M(+9.3%) |
| Mar 2012 | - | -$2.69 M(-84.6%) | -$22.71 M(+0.0%) |
| Dec 2011 | - | -$17.46 M(+619.4%) | -$22.71 M(+185.8%) |
| Sept 2011 | - | -$2.43 M(+1633.6%) | -$7.95 M(-7.9%) |
| June 2011 | -$8.63 M(-198.6%) | -$140.00 K(-94.8%) | -$8.63 M(-288.2%) |
| Mar 2011 | - | -$2.69 M(-0.4%) | $4.58 M(+0.4%) |
| Dec 2010 | - | -$2.69 M(-13.3%) | $4.57 M(-36.9%) |
| Sept 2010 | - | -$3.11 M(-123.8%) | $7.24 M(-17.3%) |
| June 2010 | $8.75 M(-448.6%) | $13.07 M(-583.3%) | $8.75 M(-280.3%) |
| Mar 2010 | - | -$2.71 M(>+9900.0%) | -$4.85 M(+74.3%) |
| Dec 2009 | - | -$24.00 K(-98.5%) | -$2.79 M(-23.3%) |
| Sept 2009 | - | -$1.59 M(+197.9%) | -$3.63 M(+44.6%) |
| June 2009 | -$2.51 M(-96.7%) | -$534.00 K(-16.0%) | -$2.51 M(-96.2%) |
| Mar 2009 | - | -$636.00 K(-26.9%) | -$65.56 M(-6.9%) |
| Dec 2008 | - | -$870.00 K(+84.7%) | -$70.42 M(-6.5%) |
| Sept 2008 | - | -$471.00 K(-99.3%) | -$75.35 M(-0.4%) |
| June 2008 | -$75.67 M(-27.0%) | -$63.58 M(+1055.8%) | -$75.67 M(+196.4%) |
| Mar 2008 | - | -$5.50 M(-5.1%) | -$25.53 M(-11.2%) |
| Dec 2007 | - | -$5.79 M(+628.9%) | -$28.73 M(-14.3%) |
| Sept 2007 | - | -$795.00 K(-94.1%) | -$33.55 M(-797.5%) |
| June 2007 | -$103.67 M(+395.7%) | -$13.44 M(+54.4%) | $4.81 M(-66.1%) |
| Mar 2007 | - | -$8.71 M(-17.9%) | $14.21 M(-17.8%) |
| Dec 2006 | - | -$10.61 M(-128.2%) | $17.29 M(-21.9%) |
| Sept 2006 | - | $37.56 M(-1029.0%) | $22.13 M(-203.3%) |
| June 2006 | -$20.91 M(+64.0%) | -$4.04 M(-28.1%) | -$21.43 M(-0.8%) |
| Mar 2006 | - | -$5.62 M(-2.5%) | -$21.59 M(+14.7%) |
| Dec 2005 | - | -$5.76 M(-3.8%) | -$18.81 M(+18.1%) |
| Sept 2005 | - | -$5.99 M(+42.5%) | -$15.92 M(+26.3%) |
| June 2005 | -$12.75 M(+398.3%) | -$4.21 M(+47.7%) | -$12.61 M(+42.4%) |
| Mar 2005 | - | -$2.85 M(-0.9%) | -$8.85 M(+32.0%) |
| Dec 2004 | - | -$2.87 M(+7.3%) | -$6.71 M(+48.2%) |
| Sept 2004 | - | -$2.68 M(+495.0%) | -$4.52 M(+83.0%) |
| June 2004 | -$2.56 M(+37.8%) | -$450.10 K(-36.0%) | -$2.47 M(-5.9%) |
| Mar 2004 | - | -$703.10 K(+1.5%) | -$2.63 M(+12.2%) |
| Dec 2003 | - | -$692.80 K(+10.6%) | -$2.34 M(+15.0%) |
| Sept 2003 | - | -$626.20 K(+3.7%) | -$2.04 M(+14.1%) |
| June 2003 | -$1.86 M(-17.5%) | -$603.80 K(+44.4%) | -$1.78 M(+51.1%) |
| Mar 2003 | - | -$418.00 K(+7.8%) | -$1.18 M(+54.8%) |
| Dec 2002 | - | -$387.80 K(+3.3%) | -$763.20 K(+103.3%) |
| Sept 2002 | - | -$375.40 K | -$375.40 K |
| June 2002 | -$2.25 M(+418.1%) | - | - |
| June 2001 | -$434.60 K | - | - |
FAQ
- What is EyePoint Pharmaceuticals annual net profit?
- What is the all time high annual net income for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual net income year-on-year change?
- What is EyePoint Pharmaceuticals quarterly net profit?
- What is the all time high quarterly net income for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly net income year-on-year change?
- What is EyePoint Pharmaceuticals TTM net profit?
- What is the all time high TTM net income for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals TTM net income year-on-year change?
What is EyePoint Pharmaceuticals annual net profit?
The current annual net income of EYPT is -$70.80 M
What is the all time high annual net income for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual net profit is $8.75 M
What is EyePoint Pharmaceuticals annual net income year-on-year change?
Over the past year, EYPT annual net profit has changed by +$31.46 M (+30.77%)
What is EyePoint Pharmaceuticals quarterly net profit?
The current quarterly net income of EYPT is -$29.36 M
What is the all time high quarterly net income for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly net profit is $37.56 M
What is EyePoint Pharmaceuticals quarterly net income year-on-year change?
Over the past year, EYPT quarterly net profit has changed by -$16.75 M (-132.80%)
What is EyePoint Pharmaceuticals TTM net profit?
The current TTM net income of EYPT is -$103.57 M
What is the all time high TTM net income for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high TTM net profit is $22.13 M
What is EyePoint Pharmaceuticals TTM net income year-on-year change?
Over the past year, EYPT TTM net profit has changed by -$3.42 M (-3.42%)